Evidence map›Paper›PMID 26768243›Full record

ReviewAnnual review of medicine2016

Acute Kidney Injury.

Anna Zuk, Joseph V Bonventre

Open access · bronzeAbstract readReview
In one paragraph

Review in Annual review of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 400 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
400citing papers in PubMed, 4 pooled it
47.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

400 citing papers in PubMed, 4 syntheses or guidelines pooled it, 740 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. NAT10-mediated acCellular & molecular biology letters · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Review

340 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anna ZukRenal Division, Brigham and Women's Hospital, Boston, Massachusetts 02115; email: drazukphd@yahoo.com.
Joseph V BonventreRenal Division, Brigham and Women's Hospital, Boston, Massachusetts 02115; email: drazukphd@yahoo.com.
Brigham and Women's Hospital · US

Funding

KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIRR01DK072381 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2025
$8.6M
Mechanisms of Ischemic Kidney Injury and RepairR01DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JOSEPH VINCENT BONVENTRE · 1987 to 2026
$6.2M
Mechanisms of Ischemic Kidney Injury and RepairR37DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1993 to 2021
$5.2M
NIDDK NIH HHS DK39773NIDDK NIH HHS DK72381NIDDK NIH HHS R01 DK039773NIDDK NIH HHS R01 DK072381NIDDK NIH HHS R37 DK039773
6 · The paper itself

Abstract

Acute kidney injury (AKI) is a global public health concern associated with high morbidity, mortality, and healthcare costs. Other than dialysis, no therapeutic interventions reliably improve survival, limit injury, or speed recovery. Despite recognized shortcomings of in vivo animal models, the underlying pathophysiology of AKI and its consequence, chronic kidney disease (CKD), is rich with biological targets. We review recent findings relating to the renal vasculature and cellular stress responses, primarily the intersection of the unfolded protein response, mitochondrial dysfunction, autophagy, and the innate immune response. Maladaptive repair mechanisms that persist following the acute phase promote inflammation and fibrosis in the chronic phase. Here macrophages, growth-arrested tubular epithelial cells, the endothelium, and surrounding pericytes are key players in the progression to chronic disease. Better understanding of these complex interacting pathophysiological mechanisms, their relative importance in humans, and the utility of biomarkers will lead to therapeutic strategies to prevent and treat AKI or impede progression to CKD or end-stage renal disease (ESRD).

Indexed as

Abbreviated Injury ScaleAcute Kidney InjuryAnimalsAutophagyBiomarkersEndoplasmic Reticulum StressHumansInflammationKidneyMicrovesselsMitochondriaBiomarkersbiomarkerschronic kidney disease progressionmaladaptive repairnephrotoxicitypathophysiologyrenal ischemia-reperfusion

Identifiers

PMID26768243
PMCPMC4845743
OpenAlexW2233632661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.